{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:58:12Z","timestamp":1793059092383,"version":"4.5.0"},"reference-count":179,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004593","name":"Universidad Autonoma de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.kint.2022.10.030","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T01:13:03Z","timestamp":1670202783000},"page":"282-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":356,"title":["Targeting inflammation to treat diabetic kidney disease: the road to 2030"],"prefix":"10.1016","volume":"103","author":[{"given":"Sandra","family":"Rayego-Mateos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul R","family":"Rodrigues-Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Fernandez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mora-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Marchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Donate-Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Navarro-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ruiz-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2022.10.030_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ckj\/sfab170","volume":"15","author":"Ortiz","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2022.10.030_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.7326\/M20-5938","article-title":"Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline","volume":"174","author":"Navaneethan","year":"2021","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"10.1016\/j.kint.2022.10.030_bib3","first-page":"S175","article-title":"11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes\u20132022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.10.030_bib4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ckj\/sfaa198","article-title":"SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia","volume":"13","author":"Fernandez-Fernandez","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2022.10.030_bib5","doi-asserted-by":"crossref","unstructured":"Ortiz A, Ferro CJ, Balafa O, et al. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrol Dial Transplant. Published online May 4, 2021. https:\/\/doi.org\/10.1093\/ndt\/gfab167","DOI":"10.1093\/ndt\/gfab167"},{"key":"10.1016\/j.kint.2022.10.030_bib6","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.10.030_bib7","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.10.030_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41581-019-0248-y","article-title":"Targeting the progression of chronic kidney disease","volume":"16","author":"Ruiz-Ortega","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8050137","article-title":"Bibliometric study of trends in the diabetic nephropathy research space from 2016 to 2020","volume":"2022","author":"Shao","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.kint.2022.10.030_bib10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/13543784.2016.1196184","article-title":"Targeting inflammation in diabetic kidney disease: early clinical trials","volume":"25","author":"Perez-Gomez","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.kint.2022.10.030_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2014.74","article-title":"Therapeutic approaches to diabetic nephropathy\u2014beyond the RAS","volume":"10","author":"Fernandez-Fernandez","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib12","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.3390\/ijms21113798","article-title":"Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy","volume":"21","author":"Rayego-Mateos","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2022.10.030_bib13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ki.2008.425","article-title":"EMT and proteinuria as progression factors","volume":"75","author":"Strutz","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.10.030_bib14","doi-asserted-by":"crossref","first-page":"F1589","DOI":"10.1152\/ajprenal.00142.2008","article-title":"Disease-dependent mechanisms of albuminuria","volume":"295","author":"Comper","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"issue":"suppl 4","key":"10.1016\/j.kint.2022.10.030_bib15","doi-asserted-by":"crossref","first-page":"iv6","DOI":"10.1093\/ndt\/gfs426","article-title":"Klotho, phosphate and inflammation\/ageing in chronic kidney disease","volume":"27","author":"Izquierdo","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2022.10.030_bib16","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.3390\/ijms21072632","article-title":"Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities","volume":"21","author":"Opazo-R\u00edos","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2022.10.030_bib17","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1681\/ASN.2010020218","article-title":"NF-\u03baB in renal inflammation","volume":"21","author":"Sanz","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib18","first-page":"18","article-title":"Oxidative stress and inflammation in renal and cardiovascular complications of diabetes","volume":"10","author":"Charlton","year":"2020","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.kint.2022.10.030_bib19","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.2337\/db10-1181","article-title":"Transcriptome analysis of human diabetic kidney disease","volume":"60","author":"Woroniecka","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2022.10.030_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120490","article-title":"Mechanistic insights into glucose induced vascular epigenetic reprogramming in type 2 diabetes","volume":"298","author":"Dhawan","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.kint.2022.10.030_bib21","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3390\/ijms21082806","article-title":"Macrophage phenotype and fibrosis in diabetic nephropathy","volume":"21","author":"Calle","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2022.10.030_bib22","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1093\/ndt\/gfh207","article-title":"NF-\u03baB activation and overexpression of regulated genes in human diabetic nephropathy","volume":"19","author":"Mezzano","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2022.10.030_bib23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2741\/2692","article-title":"Macrophage activation and polarization","volume":"13","author":"Martinez","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.kint.2022.10.030_bib24","first-page":"272","article-title":"Could IL-17A be a novel therapeutic target in diabetic nephropathy?","volume":"9","author":"Lavoz","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.kint.2022.10.030_bib25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00125-006-0497-8","article-title":"Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db\/db mice","volume":"50","author":"Chow","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2022.10.030_bib26","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfs555","article-title":"Blockade of CCL2\/CCR2 signalling ameliorates diabetic nephropathy in db\/db mice","volume":"28","author":"Seok","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2022.10.030_bib27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/13543784.2018.1538352","article-title":"Targeting inflammation in diabetic nephropathy: a tale of hope","volume":"27","author":"Moreno","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.kint.2022.10.030_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.688060","article-title":"Role of macrophages and related cytokines in kidney disease","volume":"8","author":"Cantero-Navarro","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.kint.2022.10.030_bib29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/jdi.13725","article-title":"Role of the adaptive immune system in diabetic kidney disease","volume":"13","author":"Kong","year":"2022","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.kint.2022.10.030_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7495629","article-title":"The signaling of cellular senescence in diabetic nephropathy","volume":"2019","author":"Xiong","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.kint.2022.10.030_bib31","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/ijms23031542","article-title":"Molecular mechanisms of kidney injury and repair","volume":"23","author":"Rayego-Mateos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2022.10.030_bib32","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1681\/ASN.2010101073","article-title":"The inflammatory cytokines TWEAK and TNF\u03b1 reduce renal klotho expression through NF\u03baB","volume":"22","author":"Moreno","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41581-019-0185-9","article-title":"Immunology of the ageing kidney","volume":"15","author":"Sato","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11892-020-01314-y","article-title":"Role of senescent renal cells in pathophysiology of diabetic kidney disease","volume":"20","author":"Wiley","year":"2020","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.kint.2022.10.030_bib35","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.kint.2022.06.030","article-title":"Cellular communication network 2 (connective tissue growth factor) aggravates acute DNA damage and subsequent DNA damage response-senescence-fibrosis following kidney ischemia reperfusion injury","volume":"102","author":"Valentijn","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.10.030_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.trsl.2019.07.005","article-title":"Increased renal cellular senescence in murine high-fat diet: effect of the senolytic drug quercetin","volume":"213","author":"Kim","year":"2019","journal-title":"Transl Res"},{"key":"10.1016\/j.kint.2022.10.030_bib37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease","volume":"47","author":"Hickson","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.kint.2022.10.030_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1681\/ASN.2015040405","article-title":"Necroinflammation in kidney disease","volume":"27","author":"Mulay","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.06.008","article-title":"High glucose-induced apoptosis and necroptosis in podocytes is regulated by UCHL1 via RIPK1\/RIPK3 pathway","volume":"382","author":"Xu","year":"2019","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.kint.2022.10.030_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.662020","article-title":"Acute kidney injury is aggravated in aged mice by the exacerbation of proinflammatory processes","volume":"12","author":"Marquez-Exposito","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2022.10.030_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.778776","article-title":"Kidney microRNA expression pattern in type 2 diabetic nephropathy in BTBR ob\/ob mice","volume":"13","author":"Opazo-R\u00edos","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2022.10.030_bib42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrneph.2017.142","article-title":"Modelling diabetic nephropathy in mice","volume":"14","author":"Azushima","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib43","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.kint.2018.12.031","article-title":"Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy","volume":"95","author":"Lavoz","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.10.030_bib44","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1172\/JCI129186","article-title":"Metabolically healthy obesity: facts and fantasies","volume":"129","author":"Smith","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2022.10.030_bib45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.10.030_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","article-title":"Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes","volume":"27","author":"Wagner","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2022.10.030_bib47","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41591-022-01790-7","article-title":"Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes","volume":"28","author":"Nair","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2022.10.030_bib48","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(21)00591-2","article-title":"Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants","volume":"397","author":"Syn","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.10.030_bib49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S2213-8587(17)30061-X","article-title":"Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study","volume":"5","author":"Carlsson","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.10.030_bib50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2213-8587(22)00005-5","article-title":"Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study","volume":"10","author":"Raverdy","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.10.030_bib51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3724\/abbs.2022055","article-title":"Albumin-induced premature senescence in human renal proximal tubular cells and its relationship with intercellular fibrosis","volume":"54","author":"Lu","year":"2022","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.kint.2022.10.030_bib52","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/ndt\/gfx376","article-title":"Albumin downregulates Klotho in tubular cells","volume":"33","author":"Fernandez-Fernandez","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2022.10.030_bib53","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.116.303697","article-title":"Inflammation, immunity, and hypertensive end-organ damage","volume":"116","author":"McMaster","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2022.10.030_bib54","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ckj\/sfab273","article-title":"The ERA Registry Annual Report 2019: summary and age comparisons","volume":"15","author":"Boenink","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2022.10.030_bib55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2022.10.030_bib56","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2022.10.030_bib57","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17512433.2022.2094770","article-title":"Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes","volume":"15","author":"Lerma","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.kint.2022.10.030_bib58","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.10.030_bib59","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4183\/aeb.2020.487","article-title":"The expanding class of mineralocorticoid receptor modulators: new ligands for kidney, cardiac, vascular, systemic and behavioral selective actions","volume":"16","author":"B\u0103dil\u0103","year":"2020","journal-title":"Acta Endocrinol (Buchar)"},{"key":"10.1016\/j.kint.2022.10.030_bib60","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2022.10.030_bib61","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/ndt\/gfac046","article-title":"SGLT2 inhibitors and finerenone: one or the other or both?","volume":"37","author":"Neuen","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2022.10.030_bib62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2022.10.030_bib63","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/HJH.0000000000002776","article-title":"Sodium\u2013glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun","volume":"39","author":"Sarafidis","year":"2021","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kint.2022.10.030_bib64","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/ndt\/gfz137","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease: a consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA","volume":"35","author":"Sarafidis","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2022.10.030_bib65","first-page":"191","article-title":"Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation","volume":"48","author":"Ishibashi","year":"2016","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.kint.2022.10.030_bib66","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129034","article-title":"Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2022.10.030_bib67","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.3390\/ijms22105089","article-title":"Empagliflozin inhibits IL-1\u03b2-mediated inflammatory response in human proximal tubular cells","volume":"22","author":"Pirklbauer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2022.10.030_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212408","article-title":"Empagliflozin ameliorates free fatty acid induced-lipotoxicity in renal proximal tubular cells via the PPAR\u03b3\/CD36 pathway in obese mice","volume":"22","author":"Huang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2022.10.030_bib69","article-title":"Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways","volume":"2021","author":"Lee","year":"2021","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.kint.2022.10.030_bib70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"Xu","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.kint.2022.10.030_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174715","article-title":"Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages","volume":"918","author":"Abdollahi","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.kint.2022.10.030_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2022.10.030_bib73","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.kint.2022.10.030_bib74","doi-asserted-by":"crossref","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","article-title":"Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus","volume":"304","author":"Vallon","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2022.10.030_bib75","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00210-018-1544-y","article-title":"Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression","volume":"391","author":"Abbas","year":"2018","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.kint.2022.10.030_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113677","article-title":"Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: a clinical and experimental study","volume":"154","author":"Mora-Fern\u00e1ndez","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.kint.2022.10.030_bib77","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/dom.14503","article-title":"Sodium-glucose cotransporter-2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body-induced NRF2 activation","volume":"23","author":"Kim","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2022.10.030_bib78","doi-asserted-by":"crossref","first-page":"E007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective effects of sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.kint.2022.10.030_bib79","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/path.5282","article-title":"PGC-1\u03b1 deficiency causes spontaneous kidney inflammation and increases the severity of nephrotoxic AKI","volume":"249","author":"Fontecha-Barriuso","year":"2019","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.kint.2022.10.030_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109487","article-title":"Ketogenesis impact on liver metabolism revealed by proteomics of lysine \u03b2-hydroxybutyrylation","volume":"36","author":"Koronowski","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.kint.2022.10.030_bib81","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.3390\/ijms21114113","article-title":"Epigenetic modifiers as potential therapeutic targets in diabetic kidney disease","volume":"21","author":"Martinez-Moreno","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2022.10.030_bib82","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2022.10.030_bib83","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/dia.2018.0169","article-title":"Effect of canagliflozin on urinary albumin excretion in Japanese patients with type 2 diabetes mellitus and microalbuminuria: a pilot study","volume":"20","author":"Osonoi","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.kint.2022.10.030_bib84","first-page":"1814","article-title":"The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes","volume":"8","author":"Iannantuoni","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.kint.2022.10.030_bib85","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2022.10.030_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107590","article-title":"Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria\u2014a double blind randomized placebo-controlled crossover trial","volume":"34","author":"Eickhoff","year":"2020","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.kint.2022.10.030_bib87","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-021-01264-z","article-title":"Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial","volume":"20","author":"Sposito","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.kint.2022.10.030_bib88","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.10.030_bib89","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40360-017-0172-3","article-title":"Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells","volume":"18","author":"Chang","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.kint.2022.10.030_bib90","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2022.10.030_bib91","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/08977194.2015.1125349","article-title":"Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice","volume":"33","author":"Sancar-Bas","year":"2015","journal-title":"Growth Factors"},{"key":"10.1016\/j.kint.2022.10.030_bib92","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.2337\/db17-1212","article-title":"Glucagon-like peptide 1 and its cleavage products are renoprotective in murine diabetic nephropathy","volume":"67","author":"Moellmann","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2022.10.030_bib93","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.10.030_bib94","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.10.030_bib95","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2022.10.030_bib96","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10157-020-01917-5","article-title":"Bardoxolone methyl: drug development for diabetic kidney disease","volume":"24","author":"Kanda","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib97","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ki.2012.439","article-title":"Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease","volume":"83","author":"Ruiz","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.10.030_bib98","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3892\/mmr.2021.12157","article-title":"Hydrogen sulfide attenuates renal I\/R-induced activation of the inflammatory response and apoptosis via regulating Nrf2-mediated NLRP3 signaling pathway inhibition","volume":"24","author":"Su","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.kint.2022.10.030_bib99","doi-asserted-by":"crossref","first-page":"e00099","DOI":"10.1128\/MCB.00099-20","article-title":"The molecular mechanisms regulating the KEAP1-NRF2 pathway","volume":"40","author":"Baird","year":"2020","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.kint.2022.10.030_bib100","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9372182","article-title":"Activators and inhibitors of NRF2: a review of their potential for clinical development","volume":"2019","author":"Robledinos-Ant\u00f3n","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.kint.2022.10.030_bib101","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/antiox10010039","article-title":"Protective role of Nrf2 in renal disease","volume":"10","author":"Guerrero-Hue","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.kint.2022.10.030_bib102","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.10.030_bib103","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.10.030_bib104","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","article-title":"Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study)","volume":"5","author":"Nangaku","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2022.10.030_bib105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diabet.2018.05.010","article-title":"Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double-blind placebo-controlled clinical trial","volume":"45","author":"Sattarinezhad","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.kint.2022.10.030_bib106","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3390\/antiox11061112","article-title":"Nrf2 activation in chronic kidney disease: promises and pitfalls","volume":"11","author":"Aranda-Rivera","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.kint.2022.10.030_bib107","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/HYPERTENSIONAHA.119.12105","article-title":"Endothelin: 30 years from discovery to therapy","volume":"74","author":"Barton","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2022.10.030_bib108","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/13543784.2017.1325872","article-title":"Atrasentan for the treatment of diabetic nephropathy","volume":"26","author":"Egido","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.kint.2022.10.030_bib109","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1681\/ASN.2006030208","article-title":"Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism","volume":"18","author":"Sasser","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-012-2316-4","article-title":"Endothelin antagonists in hypertension and kidney disease","volume":"28","author":"Meyers","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib111","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib112","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.10.030_bib113","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","article-title":"Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"21","author":"Stasch","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.kint.2022.10.030_bib114","doi-asserted-by":"crossref","first-page":"F685","DOI":"10.1152\/ajprenal.00280.2004","article-title":"Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis","volume":"288","author":"Hohenstein","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2022.10.030_bib115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2215\/CJN.08410520","article-title":"Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease: a randomized placebo-controlled clinical trial","volume":"16","author":"Hanrahan","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib116","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/jpet.115.230706","article-title":"A\u00a0soluble guanylate cyclase activator inhibits the progression of diabetic nephropathy in the ZSF1 rat","volume":"356","author":"Boustany-Kari","year":"2016","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.kint.2022.10.030_bib117","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s00210-021-02149-4","article-title":"Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease","volume":"394","author":"B\u00e9nardeau","year":"2021","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.kint.2022.10.030_bib118","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1124\/jpet.117.247429","article-title":"Pharmacological characterization of IW-1973, a novel soluble guanylate cyclase stimulator with extensive tissue distribution, antihypertensive, anti-inflammatory, and antifibrotic effects in preclinical models of disease","volume":"365","author":"Tobin","year":"2018","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.kint.2022.10.030_bib119","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1681\/ASN.2007091048","article-title":"The role of inflammatory cytokines in diabetic nephropathy","volume":"19","author":"Navarro-Gonz\u00e1lez","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib120","article-title":"Inflammatory cytokines in diabetic kidney disease: pathophysiologic and therapeutic implications","volume":"7","author":"Donate-Correa","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.kint.2022.10.030_bib121","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cytogfr.2009.02.005","article-title":"Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy","volume":"20","author":"Navarro-Gonz\u00e1lez","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.kint.2022.10.030_bib122","doi-asserted-by":"crossref","first-page":"F697","DOI":"10.1152\/ajprenal.00016.2008","article-title":"MCP-1\/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy","volume":"294","author":"Tesch","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2022.10.030_bib123","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","article-title":"A\u00a0signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes","volume":"25","author":"Niewczas","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2022.10.030_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN110223","article-title":"PRONEDI study investigators. Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy","volume":"97","author":"Sanchez-Alamo","year":"2022","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib125","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00296-014-3146-4","article-title":"Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease","volume":"35","author":"Kim","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.kint.2022.10.030_bib126","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.2006.069211","article-title":"Anti-tumour necrosis factor alpha therapy in patients with impaired renal function","volume":"66","author":"Hueber","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2022.10.030_bib127","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease","volume":"71","author":"Ridker","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2022.10.030_bib128","first-page":"1325","article-title":"Horizon 2020 in diabetic kidney disease: the clinical trial pipeline for add-on therapies on top of renin-angiotensin system blockade","volume":"4","author":"Perez-Gomez","year":"2015","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.kint.2022.10.030_bib129","first-page":"307","article-title":"C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria","volume":"32","author":"Menne","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2022.10.030_bib130","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ekir.2018.07.010","article-title":"Effect of PF-04634817, an oral CCR2\/5 chemokine receptor antagonist, on albuminuria in adults with overt diabetic nephropathy","volume":"3","author":"Gale","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2022.10.030_bib131","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.10.030_bib132","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1681\/ASN.2015080898","article-title":"Mitogen-activated protein kinase 14 promotes AKI","volume":"28","author":"Ortiz","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib133","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.34067\/KID.0002562022","article-title":"ASK1 inhibitor in chronic kidney disease therapy: from bench to bedside","volume":"3","author":"Wen","year":"2022","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2022.10.030_bib134","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1681\/ASN.2018121231","article-title":"Effects of selonsertib in patients with diabetic kidney disease","volume":"30","author":"Chertow","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib135","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41581-018-0023-5","article-title":"Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases","volume":"14","author":"Shi","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib136","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/sctm.19-0419","article-title":"A\u00a0systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease","volume":"10","author":"Hickson","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.kint.2022.10.030_bib137","doi-asserted-by":"crossref","DOI":"10.1038\/srep34842","article-title":"Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes","volume":"6","author":"Nagaishi","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2022.10.030_bib138","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s13287-020-01852-y","article-title":"Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis","volume":"11","author":"Xiang","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.kint.2022.10.030_bib139","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s13287-019-1474-8","article-title":"Treatment with adipose tissue-derived mesenchymal stem cells exerts anti-diabetic effects, improves long-term complications, and attenuates inflammation in type 2 diabetic rats","volume":"10","author":"Yu","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.kint.2022.10.030_bib140","first-page":"1316","article-title":"Urine-derived stem cells for the therapy of diabetic nephropathy mouse model","volume":"24","author":"Xiong","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.kint.2022.10.030_bib141","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.kint.2022.10.030_bib142","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/ckj\/sfac143","article-title":"Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease","volume":"15","author":"Donate-Correa","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2022.10.030_bib143","doi-asserted-by":"crossref","first-page":"292","DOI":"10.34067\/KID.0001252019","article-title":"Targeting inflammation in diabetic kidney disease: is there a role for pentoxifylline?","volume":"1","author":"Leehey","year":"2020","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2022.10.030_bib144","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(99)70182-4","article-title":"Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration","volume":"33","author":"Navarro","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2022.10.030_bib145","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1681\/ASN.2005010001","article-title":"Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial","volume":"16","author":"Navarro","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib146","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/j.ajkd.2008.05.012","article-title":"Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial","volume":"52","author":"Lin","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2022.10.030_bib147","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/sj.ki.5000302","article-title":"Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases","volume":"69","author":"Chen","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.10.030_bib148","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc18-0078","article-title":"Effects of pentoxifylline on soluble Klotho concentrations and renal tubular cell expression in diabetic kidney disease","volume":"41","author":"Navarro-Gonz\u00e1lez","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.10.030_bib149","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial","volume":"26","author":"Navarro-Gonz\u00e1lez","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib150","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfx008","article-title":"A\u00a0systematic review and meta-analysis of genetic association studies for the role of inflammation and the immune system in diabetic nephropathy","volume":"10","author":"Tziastoudi","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2022.10.030_bib151","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s42003-022-03448-z","article-title":"Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals","volume":"5","author":"Winkler","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.kint.2022.10.030_bib152","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2012040338","article-title":"Uromodulin triggers IL-1\u03b2-dependent innate immunity via the NLRP3 inflammasome","volume":"23","author":"Darisipudi","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib153","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/db17-0914","article-title":"A\u00a0genome-wide association study of diabetic kidney disease in subjects with type 2 diabetes","volume":"67","author":"van Zuydam","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2022.10.030_bib154","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139927","article-title":"Biomarkers of inflammation and repair in kidney disease progression","volume":"131","author":"Puthumana","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2022.10.030_bib155","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13654","article-title":"Uromodulin deficiency alters tubular injury and interstitial inflammation but not fibrosis in experimental obstructive nephropathy","volume":"6","author":"Maydan","year":"2018","journal-title":"Physiol Rep"},{"key":"10.1016\/j.kint.2022.10.030_bib156","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141801","article-title":"Transcriptome-wide association analysis identifies DACH1 as a kidney disease risk gene that contributes to fibrosis","volume":"131","author":"Doke","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2022.10.030_bib157","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141279","article-title":"DACH1 protects podocytes from experimental diabetic injury and modulates PTIP-H3K4Me3 activity","volume":"131","author":"Cao","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2022.10.030_bib158","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128886","article-title":"Functional methylome analysis of human diabetic kidney disease","volume":"4","author":"Park","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2022.10.030_bib159","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4161\/epi.27161","article-title":"DNA hypermethylation and DNA hypomethylation is present at different loci in chronic kidney disease","volume":"9","author":"Smyth","year":"2014","journal-title":"Epigenetics"},{"key":"10.1016\/j.kint.2022.10.030_bib160","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2337\/diabetes.54.4.1171","article-title":"Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy","volume":"54","author":"Shimazaki","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2022.10.030_bib161","doi-asserted-by":"crossref","first-page":"9985","DOI":"10.3390\/ijms22189985","article-title":"Development of biomarkers and molecular therapy based on inflammatory genes in diabetic nephropathy","volume":"22","author":"Maiti","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2022.10.030_bib162","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s13402-022-00680-x","article-title":"Role of ELMO1 in inflammation and cancer\u2014clinical implications","volume":"45","author":"Tocci","year":"2022","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1016\/j.kint.2022.10.030_bib163","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/sj.ki.5001939","article-title":"ELMO1 increases expression of extracellular matrix proteins and inhibits cell adhesion to ECMs","volume":"70","author":"Shimazaki","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.10.030_bib164","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41590-018-0293-x","article-title":"A\u00a0noncanonical role for the engulfment gene ELMO1 in neutrophils that promotes inflammatory arthritis","volume":"20","author":"Arandjelovic","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.kint.2022.10.030_bib165","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.nefroe.2020.09.006","article-title":"Ferroptosis and kidney disease","volume":"40","author":"Martin-Sanchez","year":"2020","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.kint.2022.10.030_bib166","doi-asserted-by":"crossref","first-page":"29013","DOI":"10.1073\/pnas.2005905117","article-title":"Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease","volume":"117","author":"Sheng","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2022.10.030_bib167","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200198R","article-title":"C-reactive protein inhibits C3a\/C3aR-dependent podocyte autophagy in favor of diabetic kidney disease","volume":"36","author":"Zhang","year":"2022","journal-title":"FASEB J"},{"key":"10.1016\/j.kint.2022.10.030_bib168","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.147716","article-title":"Complement factor B in high glucose-induced podocyte injury and diabetic kidney disease","volume":"6","author":"Lu","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2022.10.030_bib169","doi-asserted-by":"crossref","first-page":"19619","DOI":"10.1073\/pnas.1908706116","article-title":"The single-cell transcriptomic landscape of early human diabetic nephropathy","volume":"116","author":"Wilson","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2022.10.030_bib170","first-page":"291","article-title":"C3c deposition predicts worse renal outcomes in patients with biopsy-proven diabetic kidney disease in type 2 diabetes mellitus","volume":"14","author":"Li","year":"2022","journal-title":"J\u00a0Diabetes"},{"key":"10.1016\/j.kint.2022.10.030_bib171","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12014-021-09338-6","article-title":"Urine proteomics identifies biomarkers for diabetic kidney disease at different stages","volume":"18","author":"Fan","year":"2021","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.kint.2022.10.030_bib172","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2337\/db19-0043","article-title":"Complement C5a induces renal injury in diabetic kidney disease by disrupting mitochondrial metabolic agility","volume":"69","author":"Tan","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2022.10.030_bib173","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1089\/ars.2021.0125","article-title":"The complement pathway: new insights into immunometabolic signaling in diabetic kidney disease","volume":"37","author":"Tan","year":"2022","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.kint.2022.10.030_bib174","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3389\/fphar.2019.01315","article-title":"Bromodomain and extraterminal proteins as novel epigenetic targets for renal diseases","volume":"10","author":"Morgado-Pascual","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2022.10.030_bib175","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2215\/CJN.16751020","article-title":"Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial","volume":"16","author":"Kalantar-Zadeh","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib176","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1681\/ASN.2015080910","article-title":"Inhibition of bromodomain and extraterminal domain family proteins ameliorates experimental renal damage","volume":"28","author":"Suarez-Alvarez","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.10.030_bib177","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13148-019-0696-z","article-title":"Apabetalone (RVX-208) reduces vascular inflammation in\u00a0vitro and in CVD patients by a BET-dependent epigenetic mechanism","volume":"11","author":"Tsujikawa","year":"2019","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.kint.2022.10.030_bib178","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/j.ajkd.2021.11.010","article-title":"Antifibrotic agents for the management of CKD: a review","volume":"80","author":"Ruiz-Ortega","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2022.10.030_bib179","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2215\/CJN.16751221","article-title":"Extracellular vesicles as theranostic tools in kidney disease","volume":"17","author":"Huang","year":"2022","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822010171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822010171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T10:56:44Z","timestamp":1732791404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253822010171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":179,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0085253822010171"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2022.10.030","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting inflammation to treat diabetic kidney disease: the road to 2030","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2022.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}